Ignite Creation Date:
2024-05-06 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 2:12 PM
Study NCT ID:
NCT05030623
Status:
RECRUITING
Last Update Posted:
2023-11-21
First Post:
2021-08-30
Brief Title:
The Phosphodiesterase Inhibitor Tadalafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients
Sponsor:
Sadat City University
Organization:
Sadat City University
Study Overview
Official Title:
The Phosphodiesterase Inhibitor Tadalafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients Randomized Double-Blind Placebo-Controlled Trial
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Antidepressant-like effects of tadalafil to its ability to modulate transduction pathways responsible for neuroplasticity Treatment with tadalafil was shown to be PKG-dependent and lead to increased expression of cGMP pCREB BDNF and VGF in the hippocampus and prefrontal cortex PFC brain areas relevant to mood disorders pathophysiology Low-dose tadalafil improved both depressive symptoms in patients with erectile dysfunction
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None